Sentrx, the leading provider of drug safety services to the life sciences industry, and the largest hosting provider of the Oracle Argus Safety Suite announced today that Charles T. Saldarini has resigned his position as CEO and Chairman of the Board to pursue efforts with his own company, The Charles T. Saldarini Group.
“My experience with Sentrx has been excellent,” said Saldarini. “To be part of an organization that is helping bring the industry’s focus on drug safety as a commercial value driver into a sharper, more critical view has been a privilege. We do important work here, and I am pleased to leave knowing I have helped shape our approach and connect our strategy with a structure that consistently delivers that work.”
Effective immediately, the company’s President and General Manager, Michael O’Gorman, has been appointed the role of CEO and Chairman of the Board. “Chuck has made tremendous contributions to Sentrx,” said Michael O’Gorman. “Under his leadership, the Company made significant improvements in focusing on customer needs, market positioning, operating culture and overall business results, including increased revenues and profitability. Chuck’s vision for solving customer needs with leading edge technology solutions will continue to be a critical element of our plans going forward. The staff at Sentrx wishes him well and we are extremely grateful for his contributions. Chuck has agreed to remain available as a consultant and advisor.”
Sentrx is an industry leader in providing outsourced drug safety solutions comprehensive pharmacovigilance solutions. Developing from a strong foundation in adverse event case processing and related drug data system management, the company has the most experienced and expertise personnel in the full-spectrum of drug safety solutions. Sentrx integrates business process outsourcing solutions, with a focus on providing flexible and scalable solutions, backed by the Sentrx Technology Services Group (TSG) with proven tools and technology platforms, Sentrx is safety. For more information, visit the web site at http://www.Sentrx.com.
About The Charles T. Saldarini Group
The Charles T. Saldarini Group evaluates both emerging and commercial stage companies in life sciences and is typically engaged to provide executive leadership, strategic assessments for private equity investment, commercial product development and service company growth opportunities within the biopharmaceutical services industry.